Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.
about
Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working GroupBradykinin: Inflammatory Product of the Coagulation SystemAngioedema: Classification, management and emerging therapies for the perioperative physicianMultivariable confounding adjustment in distributed data networks without sharing of patient-level data.Managing data quality for a drug safety surveillance system.Angioedema in the emergency department: a practical guide to differential diagnosis and management.A consensus parameter for the evaluation and management of angioedema in the emergency department.Angiotensin-converting enzyme inhibitors and angioedema.Recurrent angioedema and the threat of asphyxiation.A systematic review of validated methods for identifying anaphylaxis, including anaphylactic shock and angioneurotic edema, using administrative and claims data.A systematic review of validated methods for identifying hypersensitivity reactions other than anaphylaxis (fever, rash, and lymphadenopathy), using administrative and claims data.Effectiveness, safety and cost of drug substitution in hypertensionPhenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system.Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.Angiotensin-converting enzyme inhibitors-induced angioedema treated by C1 esterase inhibitor concentrate (Berinert®): about one case and review of the therapeutic arsenal.Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular riskAngioedema Related to Angiotensin-Converting Enzyme Inhibitors: Attack Severity, Treatment, and Hospital Admission in a Prospective Multicenter StudyDipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.Angiotensin-converting enzyme inhibitor-associated angioedema treated with c1-esterase inhibitor: A case report and review of the literature.Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema.Angioedema: a review of 367 episodes presenting to three tertiary care hospitals.Olmesartan/amlodipine: a review of its use in the management of hypertension.Angiotensin II receptor blocker combinations: from guidelines to clinical practice.Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.Telmisartan for the reduction of cardiovascular morbidity and mortality.Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis.Drug-induced angioedema: experience of Italian emergency departments.Angiotensin converting enzyme inhibitor-related angioedema: onset, presentation, and management.Predictors of Airway Intervention in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor-Induced Angioedema.Angioedema Among Hypertensive Patients Treated with Aliskiren or Other Antihypertensive Medications in the United States.Angioedema Phenotypes: Disease Expression and Classification.Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough.Life-threatening ACE inhibitor-induced angio-oedema successfully treated with icatibant: a bradykinin receptor antagonist.Treatment of ACEI-related angioedema with icatibant: a case series.The Risk of Hypersensitivity Associated with Biologic Use among Medicare Patients with Rheumatoid Arthritis.The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety.Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association.Antihypertensive drug associated angioedema: effect modification by race/ethnicity.
P2860
Q27009012-9FEBB04E-D0A0-4F98-8C9D-BEE203F5A508Q28072738-F214AA50-9033-4A4D-9456-0244C6207230Q28076493-23BA9CD3-02A6-477D-B97F-C5CC3F567514Q30656746-BEAF3B36-663A-4921-996D-80067253A5E9Q30685299-A3A798E5-7629-4B72-8352-5AF047090894Q33559121-CDE3417F-2561-4FCA-B31B-CD8E5F1D650BQ33909577-E31E1E9C-3451-41B6-AFF9-91B74A4F670DQ33940776-433A01AA-1E0C-4AF3-AF74-DE85C80695FCQ33946601-7FD9C0C9-2758-4B30-A47A-A8030708497CQ34133939-A23451B1-5A07-42E1-BA98-47B8517956B9Q34133947-331468D2-FFE4-410A-9F47-F237192419E2Q34174844-BE1F1969-4DEC-437E-90B3-4F4BA216EF8FQ34232188-7420C390-98E8-4530-9601-A4CBEC11DD1DQ34673504-E5FCF0E7-8F19-452B-B4B2-B5F72EFB545AQ35155766-FFC4B91D-07F5-4EF3-919D-1861572D7D4AQ35539305-B8E486E3-46B2-4E69-9FB1-7F4E82F7EC49Q37016647-22808C22-573B-47FC-A697-8353833EA54BQ37378498-3ABED632-7B8F-4FED-993D-94ABAED42677Q37524447-4C13AEC1-6608-4F7D-B4B2-35A2B2B0F160Q37593085-F1BCC54B-9132-4CE1-A56C-B82D07540816Q37670834-FD22FEB4-09DB-4D82-8F7E-1A0E10573883Q37830679-7D3F17AF-1B6F-4B8C-94BA-50A39C737186Q37864949-799A40CD-CCBE-4B08-A821-4EEC045EB552Q37914851-2922C408-B8B1-44DC-ABED-7DA51459A21BQ37938745-2408F115-9569-4217-872D-3BC334B31E18Q37960631-230D145F-A26B-4900-836F-ABCE55E7451EQ38080145-C55AACAC-D237-46E6-90C3-3AB7B92D121BQ38161456-322EF734-944E-4472-BB8A-3C5F30F0F8C5Q38233590-431B1565-DCEE-4627-8639-32FAE935B0C9Q38530515-E9CBBEB4-7CA0-458C-A31B-9A4D026708A4Q38594936-D57EA49F-114F-4EE3-BDEB-5D11C9ABF5B9Q38639396-E5E1F820-C6D1-47C8-AB2D-D1451B2E2A18Q38817627-050C3107-7FB6-4968-8FC1-9CE31DA2E987Q39151600-E17E6A09-7DB3-4C95-B39B-6BF76BDAD9DEQ39181687-E7DDE58F-C8F7-408F-B2E4-492D084447ACQ39194480-98D080D3-EA1E-4006-AD3C-F9C7DCD5F76EQ39215589-EE937329-2A1D-4E83-8EA1-0EC29FBE5132Q39456476-D585370A-6D6D-4078-AEAA-0213D9B4CFD6Q39602398-CDD26360-5A87-4223-BA78-8CBDB3E4A345Q40117212-D6A4EAC1-3D92-4C4E-B84A-E4FC986F4012
P2860
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.
@en
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.
@nl
type
label
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.
@en
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.
@nl
prefLabel
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.
@en
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.
@nl
P2093
P1433
P1476
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors
@en
P2093
Benjamin G Fincke
David E Lillienfeld
Donald R Miller
Paul Stang
Susan A Oliveria
P304
P356
10.1161/HYPERTENSIONAHA.108.110270
P407
P577
2008-04-14T00:00:00Z